Mavacamten Form 7 Crystalline Polymorph for Stable Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional solid state forms of Mavacamten, including solvated forms, to improve processing properties, stability, and bioavailability, which are not adequately addressed by existing polymorphs.
Innovation Solution
The development of a crystalline polymorph of Mavacamten, designated Form 7, which is characterized by specific X-ray powder diffraction patterns and is stable under various stress conditions, including high humidity, temperature, and mechanical stress, facilitating its use in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing polymorphs of Mavacamten are used, then the compound can be formulated for pharmaceutical use, but processing properties, stability, and bioavailability are not adequately improved
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing a new crystalline polymorph (Form 7) with distinct physical parameters including X-ray diffraction pattern, melting point, and thermal behavior. This new polymorphic form exhibits improved stability and processing properties compared to existing forms, resolving the contradiction between reliability and ease of manufacture.
2Ease of operation
If additional solid state forms are discovered, then processing properties and bioavailability can be improved, but the complexity of characterizing and controlling polymorphic forms increases
Solution Approach 1:
The patent employs multiple analytical techniques including X-ray diffraction, thermogravimetric analysis, differential scanning calorimetry, and NMR spectroscopy to characterize the new polymorph. These analytical methods replace complex manual characterization processes, enabling systematic discovery and control of polymorphic forms while improving processing properties.
3Stability of the object's composition
If a new crystalline polymorph is developed, then stability and resistance to polymorphic changes are improved, but the process for preparation and characterization becomes more complex
Solution Approach 1:
The patent employs preliminary action by systematically exploring various crystallization conditions and stress parameters before obtaining the stable Form 7. The compound is subjected to controlled stress conditions (temperature, humidity, mechanical stress) to induce and stabilize the desired polymorphic form, ensuring resistance to further polymorphic changes while managing preparation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Form 7 of Mavacamten offers improved stability, non-hygroscopicity, and resistance to polymorphic changes, making it suitable for pharmaceutical formulations and treatments, particularly for obstructive hypertrophic cardiomyopathy.
Implementation Method 1
One or more of these techniques may be used to distinguish different polymorphic forms of a compound... a characteristic X-ray powder diffraction pattern (XRPD) of Mavacamten Form 7
Implementation Method 2
thermal behaviors (e.g., measured by thermogravimetric analysis ('TGA'), or differential scanning calorimetry ('DSC'))
Implementation Method 3
thermal behaviors (e.g., measured by thermogravimetric analysis ('TGA'), or differential scanning calorimetry ('DSC'))
Implementation Method 4
solid state (13C) NMR spectrum
Data Source
AI summary
The present disclosure encompasses a solid state form of Mavacamten, in embodiments a crystalline polymorph of Mavacamten, processes for preparation thereof, and pharmaceutical compositions thereof.